Table 2.

NAC for the treatment of methamphetamine use disorder

Study	Sample	Dosing	Outcomes
Mousavi et al18 (2015)	N = 32 treatment- seeking adults with methamphetamine dependence (83% male, 100% recruited from Iran)	1,200 mg/d vs placebo (crossover design) for 4 weeks each	Reduction in methamphetamine cravings during treatment (but not after crossover) using the Cocaine Craving Questionnaire brief (CCQ- brief)
Grant et al19 (2010)	N = 31 non- treatment seeking adults with methamphetamine dependence (71% male)	2,400 mg/d NAC plus 200 mg/d naltrexone vs placebo for 8 weeks	No reduction in craving as measured by the Penn Craving Scale or frequency of use (urine drug screen)

NAC: N-acetylcysteine